Today’s stock market focus is centered on one single sector: technology stocks. The excitement around artificial intelligence ...

Eli Lilly (LLY) ended the recent trading session at $762.18, demonstrating a -1.23% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.14% ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly stock is a no-brainer buy right now. For Eli Lilly to reach a $1 trillion market cap within the next couple of years, it would need to rise by more than 50% from where it is today.

LLY, NFLX, and GE lead today's top stock picks, with strong growth drivers but face headwinds from pricing, rivals, and costs ...

Eli Lilly's valuation might be a significant stumbling block for some investors. If the stock fails to meet the market's lofty expectations, its shares will plummet. That's what happened after the ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Eli Lilly stock is up 6.6% today and 50% for the year. Driving those gains is excitement over two potential blockbusters—one for obesity and diabetes and another for Alzheimer’s.

Parnassus Core Equity Fund sees Eli Lilly And Co. (NYSE:LLY) as a strong long-term investment due to its GLP-1 franchise and innovation, capitalizing on a sell-off to buy at an attractive valuation.

Eli Lilly's stock has surged close to 400% in five years. Eli Lilly is the most likely healthcare stock to reach a $1 trillion valuation, and I believe it could hit that plateau by 2027.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.